Related Experiment Video
Updated: Apr 1, 2026
07:14
A Novel Approach to Assess Motor Outcome of Deep Brain Stimulation Effects in the Hemiparkinsonian Rat: Staircase and Cylinder Test
Published on: May 31, 2016
15.5K
Interventional trials in atypical parkinsonism
S Eschlböck1, F Krismer1, G K Wenning1
1Department of Neurology, Medical University of Innsbruck, Anichstraße 35, 6020, Innsbruck, Austria.
Parkinsonism & Related Disorders
|October 1, 2015
Summary
Atypical parkinson disorders (APD) lack disease-modifying treatments despite research advances. Current symptomatic treatments offer limited relief, and recent trials for multiple system atrophy (MSA) and progressive supranuclear palsy (PSP) have yielded negative results.
Area of Science:
- Neuroscience
- Neurology
- Clinical Trials
Background:
- Atypical parkinson disorders (APD), including multiple system atrophy (MSA), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD), present complex, rapidly progressing neurodegenerative conditions.
- While symptomatic treatments, especially for neurogenic orthostatic hypotension, have seen advancements, overall therapeutic support remains limited.
- Currently, no effective disease-modifying treatments exist for APDs, and recent clinical trials have reported negative outcomes.
Purpose of the Study:
- To review published randomized, placebo-controlled clinical trials (RCTs) for atypical parkinson disorders (APD).
- To present the design of ongoing and unpublished intervention studies in APDs.
- To provide an overview of the current therapeutic landscape and future directions for APD research.
Main Methods:
- Systematic review of published randomized, placebo-controlled clinical trials (RCTs) in atypical parkinson disorders (APD).
- Inclusion of data from recent trials investigating drugs such as rasagiline and rifampicin (for MSA), and tideglusib and davunetide (for PSP).
- Analysis of trial methodologies and patient cohort recruitment in recent interventional studies.
Main Results:
- Recent disease-modifying trials for APDs, including those targeting MSA and PSP, have reported negative results.
- Despite trial failures, significant progress in basic research provides a foundation for future therapeutic development.
- Large patient cohorts have been recruited for interventional studies, enhancing understanding of trial methodology in APDs.
Conclusions:
- There is an urgent need for effective disease-modifying therapies for atypical parkinson disorders (APD).
- Recent clinical trial outcomes highlight the challenges in developing treatments for these conditions.
- Continued basic research and improved trial designs are crucial for advancing future therapeutic interventions in APDs.
Related Concept Videos
01:24Parkinson's Disease: Treatment
1.4K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K
01:15Parkinson's Disease: Overview
2.4K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.4K
01:16Clinical Trials
11.2K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
11.2K
01:11Clinical Trials: Overview
5.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.4K